A

Aegirbio AB
F:52Q

Watchlist Manager
Aegirbio AB
F:52Q
Watchlist
Price: 0.0455 EUR Market Closed
Market Cap: €1.6m

Net Margin

-137 155.6%
Current
Declining
by 5 657%
vs 3-y average of -131 498.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-137 155.6%
=
Net Income
kr-49.4m
/
Revenue
kr36k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-137 155.6%
=
Net Income
€-49.4m
/
Revenue
kr36k

Peer Comparison

Country Company Market Cap Net
Margin
SE
Aegirbio AB
STO:AEGIR
6.9m SEK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 99% of companies in Sweden
Percentile
1st
Based on 2 084 companies
1st percentile
-137 155.6%
Low
-5 565 412.8% — -5.3%
Typical Range
-5.3% — 7.5%
High
7.5% — 12 228%
Distribution Statistics
Sweden
Min -5 565 412.8%
30th Percentile -5.3%
Median 3%
70th Percentile 7.5%
Max 12 228%

Aegirbio AB
Glance View

Market Cap
1.6m EUR
Industry
Biotechnology

AegirBio AB engages in the development and commercialization of drug monitoring tests. The company is headquartered in Lund, Skane. The company went IPO on 2020-06-26. The firm offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.

52Q Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-137 155.6%
=
Net Income
kr-49.4m
/
Revenue
kr36k
What is Aegirbio AB's current Net Margin?

The current Net Margin for Aegirbio AB is -137 155.6%, which is below its 3-year median of -131 498.5%.

How has Net Margin changed over time?

Over the last 3 years, Aegirbio AB’s Net Margin has decreased from -133 850% to -137 155.6%. During this period, it reached a low of -370 709.1% on Sep 30, 2023 and a high of -670.7% on Sep 30, 2021.

Back to Top